Edgewise Therapeutics, Inc. (EWTX)

NASDAQ: EWTX · Real-Time Price · USD

14.87

+0.08 (0.54%)

At close: May 20, 2025, 4:00 PM

14.91

+0.04 (0.27%)

After-hours: May 20, 2025, 4:48 PM EDT

Edgewise Therapeutics Employees

Edgewise Therapeutics had 110 employees as of December 31, 2024. The number of employees increased by 22 or 25.00% compared to the previous year.

Employees

110

Change (1Y)

22

Growth (1Y)

25.00%

Revenue / Employee

n/a

Profits / Employee

-$1,328,055

Market Cap

1.57B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	110	22	25.00%
Dec 31, 2023	88	29	49.15%
Dec 31, 2022	59	28	90.32%
Dec 31, 2021	31	12	63.16%
Dec 31, 2020	19	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

EWTX News

6 days ago - Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 - PRNewsWire
12 days ago - Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
5 weeks ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga
6 weeks ago - Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On - Seeking Alpha
6 weeks ago - Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study - Benzinga
6 weeks ago - Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock - PRNewsWire
6 weeks ago - Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PRNewsWire
7 weeks ago - Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - PRNewsWire